Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"

被引：0
|
作者：
Lam, Carolyn S. P. [1 ,2 ]
Gerstein, Hertzel C. [3 ,4 ]
机构：
[1] Natl Heart Ctr Singapore, Singapore, Singapore
[2] Duke Natl Univ Singapore, Singapore, Singapore
[3] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] McMaster Univ, Hamilton, ON, Canada
来源：
CIRCULATION | 2022年 / 146卷 / 02期
关键词：
D O I：
10.1161/CIRCULATIONAHA.122.060526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E7 / E7
页数：1
相关论文
共 50 条
  • [41] Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence
    McEwan, Phil
    Bennett, Hayley
    Khunti, Kamlesh
    Wilding, John
    Edmonds, Christopher
    Thuresson, Marcus
    Wittbrodt, Eric
    Fenici, Peter
    Kosiborod, Mikhail
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2364 - 2374
  • [42] Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting
    Rosenstock, Julio
    Ali, Amar
    Meier, Juris J.
    Giorgino, Francesco
    Guja, Cristian
    Prazny, Martin
    Lubwama, Robert
    Souhami, Elisabeth
    Blonde, Lawrence
    DIABETES, 2020, 69
  • [43] Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
    Komuro, Issei
    Kadowaki, Takashi
    Bodegard, Johan
    Thuresson, Marcus
    Okami, Suguru
    Yajima, Toshitaka
    DIABETES OBESITY & METABOLISM, 2021, 23 : 19 - 27
  • [44] Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea
    Hui-Jeong Hwang
    Minji Kim
    Ji Eun Jun
    Dong Keon Yon
    Scientific Reports, 13 (1)
  • [45] Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea
    Hwang, Hui-Jeong
    Kim, Minji
    Jun, Ji Eun
    Yon, Dong Keon
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [46] Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
    Taeger, Tobias
    Atar, Dan
    Agewall, Stefan
    Katus, Hugo A.
    Grundtvig, Morten
    Cleland, John G. F.
    Clark, Andrew L.
    Froehlich, Hanna
    Frankenstein, Lutz
    HEART FAILURE REVIEWS, 2021, 26 (06) : 1421 - 1435
  • [47] Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
    Tobias Täger
    Dan Atar
    Stefan Agewall
    Hugo A. Katus
    Morten Grundtvig
    John G. F. Cleland
    Andrew L. Clark
    Hanna Fröhlich
    Lutz Frankenstein
    Heart Failure Reviews, 2021, 26 : 1421 - 1435
  • [48] Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin
    Corbin, Karen D.
    Dagogo-Jack, Samuel
    Cannon, Christopher P.
    Cherney, David Z. I.
    Cosentino, Francesco
    Frederich, Robert
    Liu, Jie
    Pong, Annpey
    Lin, Jianxin
    Cater, Nilo B.
    Pratley, Richard E.
    DIABETES OBESITY & METABOLISM, 2023, 25 (03): : 758 - 766
  • [49] EFFECTIVENESS OF INSULIN PLUS OFF LABEL USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS INSULIN ALONE IN TYPE 1 DIABETES: A REAL-WORLD OBSERVATIONAL ANALYSIS
    Silva-Almodovar, A.
    Nahata, M. C.
    VALUE IN HEALTH, 2019, 22 : S141 - S141
  • [50] Long-term cardiovascular, non-cardiovascular safety and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a systemic review and meta-analysis with trial sequential analysis
    Zhang, Xinlin
    Xu, Biao
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (18) : B332 - B333
12345